Exposure to Psychotropic Drugs and Colorectal Cancer Risk in Patients with Affective Disorder: A Nested Case-Control Study

Abstract

Background This study aimed to assess the association between the risk of colorectal cancer (CRC) and exposure to mood stabilizers, antidepressants, and antipsychotics in patients with affective disorders.

Methods This nested case-control study used data from the National Health Insurance Database of Taiwan collected between 2001 and 2011. All participants in this study had affective disorders. Then, 1209 patients with CRC and 1:10 matched controls were identified based on their demographic and clinical characteristics. A logistic regression model adjusted for demographic and clinical characteristics was used to determine the risk of developing CRC after exposure to psychotropic drugs.

Results Among patients with affective disorders, exposure to mood stabilizers (reported as odds ratio; 95% confidence interval; 0.75; 0.57–0.98), antidepressants (0.83; 0.70–0.97), second-generation antipsychotics (0.67; 0.52–0.86), and first-generation antipsychotics (0.65; 0.52–0.81) were associated with a reduced risk of CRC compared to patients who were not exposed. When considering specific drugs, carbamazepine (0.34; 0.12–0.95), valproic acid (0.66; 0.46–0.95), gabapentin (0.44; 0.20–0.99), fluoxetine (0.82; 0.68–0.99), paroxetine (0.63; 0.45–0.87), and venlafaxine (0.72; 0.55–0.95) were associated with a lower risk of CRC.

Conclusion Exposure to psychotropic drugs in patients with affective disorders is associated with a lower risk of CRC compared to those who were not exposed. Although the causal relationship between psychotropic drug exposure and reduced risk of CRC could not be inferred directly, these findings may help clinicians and patients in clinical decision-making.

Keywords

colorectal cancer - affective disorder - mood stabilizer - antidepressant - antipsychotic

^# Mu-Hung Chen and Chih-Sung Liang are co-corresponding authors of this paper and have contributed equally in this capacity.

Publication History

Received: 06 August 2024
Received: 19 October 2024

Accepted: 12 November 2024

Article published online:
17 December 2024

• References

• 1 Sawicki T, Ruszkowska M, Danielewicz A. et al. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel) 2021; 13
• 2 Fraile-Martinez O, Alvarez-Mon MA, Garcia-Montero C. et al. Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine. Front Oncol 2022; 12: 956923
• 3 Anmella G, Fico G, Lotfaliany M. et al. Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. Neurosci Biobehav Rev 2021; 126: 529-541
• 4 Jia Y, Li F, Liu YF. et al. Depression and cancer risk: A systematic review and meta-analysis. Public Health 2017; 149: 138-148
• 5 Chubak J, Boudreau DM, Rulyak SJ. et al. Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer 2011; 128: 227-232
• 6 Coogan PF, Strom BL, Rosenberg L. Antidepressant use and colorectal cancer risk. Pharmacoepidemiol Drug Saf 2009; 18: 1111-1114
• 7 Xu W, Tamim H, Shapiro S. et al. Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 2006; 7: 301-308
• 8 Takada M, Fujimoto M, Motomura H. et al. Inverse association between sodium channel-blocking antiepileptic drug use and cancer: Data mining of spontaneous reporting and claims databases. Int J Med Sci 2016; 13: 48-59
• 9 Chen VC, Hsieh YH, Lin TC. et al. New use for old drugs: The protective effect of risperidone on colorectal cancer. Cancers (Basel) 2020; 12
• 10 Dalton SO, Johansen C, Poulsen AH. et al. Cancer risk among users of neuroleptic medication: A population-based cohort study. Br J Cancer 2006; 95: 934-939
• 11 Gil-Ad I, Zolokov A, Lomnitski L. et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 2008; 33: 277-286
• 12 Akbarzadeh L, Moini Zanjani T, Sabetkasaei M. Comparison of anticancer effects of carbamazepine and valproic acid. Iran Red Crescent Med J 2016; 18: e37230
• 13 Haukka J, Sankila R, Klaukka T. et al. Incidence of cancer and antidepressant medication: Record linkage study. Int J Cancer 2010; 126: 285-296
• 14 Clemente AS, Diniz BS, Nicolato R. et al. Bipolar disorder prevalence: A systematic review and meta-analysis of the literature. Braz J Psychiatry 2015; 37: 155-161
• 15 Hasin DS, Sarvet AL, Meyers JL. et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 2018; 75: 336-346
• 16 Hammer-Helmich L, Haro JM, Jonsson B. et al. Functional impairment in patients with major depressive disorder: The 2-year PERFORM study. Neuropsychiatr Dis Treat 2018; 14: 239-249
• 17 Peters AT, West AE, Eisner L. et al. The burden of repeated mood episodes in bipolar I disorder: Results from the National Epidemiological Survey on Alcohol and Related Conditions. J Nerv Ment Dis 2016; 204: 87-94
• 18 Dickerson F, Stallings CR, Origoni AE. et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv 2013; 64: 44-50
• 19 Liu YK, Ling S, Lui LMW. et al. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. J Affect Disord 2022; 300: 449-461
• 20 Luppino FS, de Wit LM, Bouvy PF. et al. Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-229
• 21 Mathew AR, Hogarth L, Leventhal AM. et al. Cigarette smoking and depression comorbidity: Systematic review and proposed theoretical model. Addiction 2017; 112: 401-412
• 22 Puddephatt JA, Irizar P, Jones A. et al. Associations of common mental disorder with alcohol use in the adult general population: A systematic review and meta-analysis. Addiction 2022; 117: 1543-1572
• 23 Huang JS, Yang FC, Chien WC. et al. Risk of substance use disorder and its associations with comorbidities and psychotropic agents in patients with autism. JAMA Pediatr 2021; 175: e205371
• 24 Liang CS, Bai YM, Hsu JW. et al. The risk of sexually transmitted infections following first-episode schizophrenia among adolescents and young adults: A cohort study of 220 545 subjects. Schizophr Bull 2020; 46: 795-803
• 25 Hsu TW, Liang CS, Tsai SJ. et al. Risk of major psychiatric disorders among children and adolescents surviving malignancies: A nationwide longitudinal study. J Clin Oncol 2023; 41: 2054-2066
• 26 Chen MH, Hsu JW, Huang KL. et al. Risk and coaggregation of major psychiatric disorders among first-degree relatives of patients with bipolar disorder: A nationwide population-based study. Psychol Med 2019; 49: 2397-2404
• 27 Chen MH, Lan WH, Hsu JW. et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: A nationwide longitudinal study. Diabetes care 2016; 39: 788-793
• 28 Cheng CM, Chang WH, Chen MH. et al. Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: A nationwide population-based study. Molecular psychiatry 2018; 23: 1756-1763
• 29 Huang MH, Cheng CM, Tsai SJ. et al. Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: A nationwide study. Psychol Med 2020; 1-8
• 30 Liu CY, Hung YT, Chuang YL. et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Management (Chin) 2006; 4: 1-22
• 31 Charlson ME, Pompei P, Ales KL. et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383
• 32 Hsu TW, Bai YM, Tsai SJ. et al. Risk of retinal disease in patients with bipolar disorder: A nationwide cohort study. Psychiatry Clin Neurosci 2022; 76: 106-113
• 33 Hsu TW, Chen MH, Chu CS. et al. Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study. Headache 2022; 62: 634-641
• 34 Kuo HY, Liang CS, Tsai SJ. et al. Dose-dependent proton pump inhibitor exposure and risk of type 2 diabetes: A nationwide nested case-control study. Int J Environ Res Public Health 2022; 19
• 35 Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin) 2012; 6: 352-361
• 36 Wheler JJ, Janku F, Falchook GS. et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 2014; 73: 495-501
• 37 Yang M, Kozminski DJ, Wold LA. et al. Therapeutic potential for phenytoin: Targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res Treat 2012; 134: 603-615
• 38 Kim HJ, Bae SC. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3: 166-179
• 39 Ahmadi R, Sepehri B, Irani M. et al. In-silico optimization of frizzled-8 receptor inhibition activity of carbamazepine: Design new anti-cancer agent. Comb Chem High Throughput Screen 2023; 26: 696-705
• 40 Beutler AS, Li S, Nicol R. et al. Carbamazepine is an inhibitor of histone deacetylases. Life Sci 2005; 76: 3107-3115
• 41 Bilen MA, Fu S, Falchook GS. et al. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol 2015; 75: 869-874
• 42 Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E. et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006; 6: 2
• 43 Sigler RE, Gough AW, de la Iglesia FA. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology 1995; 98: 73-82
• 44 da Cunha LP, Rey MEC, Jorge DCR. et al. High dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites. BMC Res Notes 2019; 12: 59
• 45 Zhang JL, Yang JP, Zhang JR. et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res 2013; 1493: 13-18
• 46 Bugan I, Karagoz Z, Altun S. et al. Gabapentin, an analgesic used against cancer-associated neuropathic pain: Effects on prostate cancer progression in an in vivo rat model. Basic Clin Pharmacol Toxicol 2016; 118: 200-207
• 47 Huang RY, Hsieh KP, Huang WW. et al. Use of lithium and cancer risk in patients with bipolar disorder: Population-based cohort study. Br J Psychiatry 2016; 209: 393-399
• 48 Suganthi M, Sangeetha G, Gayathri G. et al. Biphasic dose-dependent effect of lithium chloride on survival of human hormone-dependent breast cancer cells (MCF-7). Biol Trace Elem Res 2012; 150: 477-486
• 49 Boursi B, Lurie I, Mamtani R. et al. Anti-depressant therapy and cancer risk: A nested case-control study. Eur Neuropsychopharmacol 2015; 25: 1147-1157
• 50 Kuwahara J, Yamada T, Egashira N. et al. Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells. Biol Pharm Bull 2015; 38: 1410-1414
• 51 Jang WJ, Jung SK, Vo TTL. et al. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J Cell Mol Med 2019; 23: 1106-1115
• 52 Kannen V, Hintzsche H, Zanette DL. et al. Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. PLoS One 2012; 7: e50043
• 53 Kannen V, Marini T, Turatti A. et al. Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. Toxicol Lett 2011; 204: 134-140
• 54 Durand JP, Alexandre J, Guillevin L. et al. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005; 16: 587-591
• 55 Rabin EE, Kim M, Mozny A. et al. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. Brain Behav Immun Health 2022; 21: 100449
• 56 Fond G, Macgregor A, Attal J. et al. Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review. Med Hypotheses 2012; 79: 38-42
• 57 Badran A, Tul-Wahab A, Zafar H. et al. Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS One 2020; 15: e0235676
• 58 Papadopoulos F, Isihou R, Alexiou GA. et al. Haloperidol induced cell cycle arrest and apoptosis in glioblastoma cells. Biomedicines 2020; 8
• 59 Dilly SJ, Clark AJ, Marsh A. et al. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett 2017; 393: 16-21
• 60 Dilly SJ, Morris GS, Taylor PC. et al. Clinical pharmacokinetics of a lipid-based formulation of risperidone, VAL401: Analysis of a single dose in an open-label trial of late-stage cancer patients. Eur J Drug Metab Pharmacokinet 2019; 44: 557-565